Canada Markets open in 3 hrs 12 mins

Charles River Laboratories International, Inc. (CRL)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
225.02-11.19 (-4.74%)
At close: 04:00PM EDT
225.02 0.00 (0.00%)
After hours: 05:10PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000
https://www.criver.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees18,600

Key Executives

NameTitlePayExercisedYear Born
Mr. James C. Foster J.D.Chairman, CEO & Pres3.28M12.05M1951
Mr. David Ross SmithCorp. Exec. VP & CFO1.38M2.38M1966
Ms. Birgit GirshickCorp. Exec. VP & COO1.18M4.04M1970
Mr. Joseph W. LaPlumeCorp. Exec. VP of Corp. Devel. & Strategy1.07MN/A1974
Mr. William D. BarboChief Commercial Officer & Corp. Exec. VP1.13M2.69M1961
Mr. Michael Gunnar KnellCorp. Sr. VP & Chief Accounting OfficerN/AN/A1977
Prof. Julie Frearson Ph.D.Corp. Sr. VP & Chief Scientific OfficerN/AN/AN/A
Mr. Mark MintzCorp. Sr. VP & Chief Information OfficerN/AN/AN/A
Todd SpencerCorp. VP of Investor RelationsN/AN/AN/A
Mr. Matthew L. DanielCorp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Corporate Governance

Charles River Laboratories International, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 4. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.